                         SEQUENCE LISTING

<110>  NPS Pharmaceuticals, Inc.
 
<120>  Treatment Methods for Gut-Mediated HIV Immune Dysfunction

<130>  50821-901

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-2 peptide consensus sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is absent, or Xaa is Arg, or Xaa is Arg-Arg

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa is a neutral/polar/large/nonaromatic residue such as Ile or 
       Val

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is a neutral/polar residue such as Asn or Ser

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is a neutral residue such as Ala or Thr

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is a neutral/polar/large/nonaromatic residue such as Ile or 
       Leu

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Xaa is a neutral or basic residue such as Gln or His

<220>
<221>  MISC_FEATURE
<222>  (35)..(35)
<223>  Xaa is absent, or Xaa is Arg, or Xaa is Lys, or Xaa is Arg-Lys, 
       or Xaa is Lys-Lys

<400>  1

Xaa His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Xaa Leu Ala 
1               5                   10                  15      


Xaa Leu Ala Xaa Arg Asp Phe Ile Asn Trp Leu Xaa Xaa Thr Lys Ile 
            20                  25                  30          


Thr Asp Xaa 
        35  


<210>  2
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-2 peptide analog consensus sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is absent, or Xaa is one or two basic amino acids selected 
       from the group Arg, Lys, and His

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is His or Tyr

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is Ala or any other amino acid conferring on said analog 
       resistance to dipeptyl peptidase IV enzyme

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is Asp or Glu

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is Gly or Ala

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is Glu-Met or an oxidatively stable amino acid-Asn-Thr-Ile, 
       or Xaa is Tyr-Ser-Lys-Tyr

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is Ala or Thr

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is Arg, Lys, His or Ala

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is Ile-Asn, or Xaa is Ile-Ala, or Xaa is Val-Gln

<220>
<221>  MISC_FEATURE
<222>  (27)..(27)
<223>  Xaa is a covalent bond, or Xaa is Ile, or Xaa is Ile-Thr, or Xaa 
       is Ile-Thr-Asp

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is absent, or Xaa is one or two basic amino acids selected 
       from the group Arg, Lys, and His

<400>  2

Xaa Xaa Xaa Xaa Xaa Ser Phe Ser Asp Xaa Leu Asp Asn Leu Ala Xaa 
1               5                   10                  15      


Xaa Asp Phe Xaa Trp Leu Ile Gln Thr Lys Xaa Xaa 
            20                  25              


<210>  3
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human GLP-2 (1-33)

<400>  3

His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  4
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Teduglutide

<400>  4

His Gly Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr 
            20                  25                  30          


Asp 
    


